Redefining Colorectal Cancer by Tumor Biology
The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Abstract
Colorectal cancer treatment has undergone a paradigm shift. We no longer see this disease as a singular, anatomic tumor type but rather a set of disease subgroups. Largely because of a better understanding of cancer biology and the introduction and integration of molecular biomarkers—the premise of precision therapy—we are beginning to direct treatments toward the right tumor target(s) in the right patients. The field of molecular profiling is continually evolving, and new biomarkers are constantly being discovered that have investigational, therapeutic, and/or prognostic implications—negative or positive. To date, only a few biomarkers have sufficient actionable, clinical implication to earn international guideline-recommended routine testing. Hence, it is vital that the treating oncologist should know which biomarkers to assess, when in the treatment course to test for them, and how the test is to be done. Correct interpretation of profiling results is imperative. Herein, we focus on international guideline-recommended mutation testing for patients prior to their colorectal cancer treatment initiation. The clinical applications of circulating tumor DNA (ctDNA) in patients with metastatic disease, based on our current knowledge and capabilities, are also addressed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Molecular testing for activating KRAS and NRAS mutations (comprehensive RAS panel) and BRAF mutations is recommended by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) to select patients for anti-EGFR therapy [23].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [23]
Citations
Cites
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationMicrosatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Kalia, S. S., Adelman, K., Bale, S. J., Chung, W. K., Eng, C., Evans, J. P., Herman, G. E., Hufnagel, S. B., Klein, T. E., Korf, B. R., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.190 · Cited by 1,644
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
Research works printed but not linked: 12
- Gutierrez ME, 2019, Precision Oncol, 3, 1
- Gupta R, 2020, J Clin Oncol, 38
- Pennell NA, 2019, Precision Oncol, 3, 1
- 10.1186/s13059-014-0454-7 · doi:10.1186/s13059-014-0454-7 · Paper page
- Mandel P, 1948, C R Seances Soc Biol Fil, 142, 241
- Sorenson GD, 1994, Cancer Epidemiol Biomarkers Prev, 3, 67
- Battaglin F, 2018, Clin Adv Hematol Oncol, 16, 735
- Thomas J, Clin Colorectal Cancer
- Lenz H-J, 2019, J Clin Oncol, 37
- Kopetz S, 2017, J Clin Oncol, 35
- Nakamura Y, 2019, Ann Oncol, 30, v198
- Sartore-Bianchi A, 2019, Ann Oncol, 30, v851
Cited by
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“…European Society for Medical Oncology (ESMO) to select patients for anti-EGFR 3 of 19 (comprehensive RAS panel) and BRAF mutations is recommended by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) to select patients for anti-EGFR therapy [23].”
BackgroundDuffy, M. J., & Crown, J. P. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac121 · Cited by 65
Duffy, M. J., & Crown, J. P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010099 · Cited by 42
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
Doleschal, B., Petzer, A., & Rumpold, H. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048166 · Cited by 40
(2025) · doi:10.1038/s41467-025-57181-2 · Cited by 34
Metadata
- Authors
- Salem, M. E., Puccini, A., & Tie, J.
- Affiliations
- Levine Cancer Institute (US)
- Ospedale Policlinico San Martino (IT)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Salem, Mohamed E.
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2020-05
- Volume
- 40
- Issue
- 40
- Pages
- 147-159
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W3012562659
- Cited by
- 14
- References
- 108
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 6 · 2021: 3 · 2020: 2
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Society of Clinical Oncology Educational Book (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- colorectal cancer, molecular biomarkers, precision oncology, molecular profiling, mutation testing, circulating tumor DNA, metastatic colorectal cancer, tumor subtypes, prognostic factors, actionable biomarkers
- MeSH terms
- Biology, Female, Humans, Male, Prognosis, Colorectal Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Redefining Colorectal Cancer by Tumor Biology. https://app.cochat.ai/papers/10.1200/edbk_279867
- The paper
- Salem, M. E., Puccini, A., & Tie, J. (2020). Redefining Colorectal Cancer by Tumor Biology. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_279867
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.